Atlas Trials

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

Clinical trial NCT06832267 · RECRUITING

Trial details

NCT number
NCT06832267
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2025-02-14
Primary completion
2027-02-13
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.